BioSpace sat down with Sharon Hesterlee, Ph.D., chief research officer at the Muscular Dystrophy Association (MDA), to talk about the history and challenges of developing gene therapy for DMD and the DMD gene therapy field as a whole, including Pfizers and Sarepta Therapeutics latest clinical data. Duchenne Muscular Dystrophy Treatment Outlook, Upcoming Potential Duchenne Muscular Dystrophy Gene Therapy, FAQ For Duchenne Muscular Dystrophy (DMD). Vast improvements have been made in managing patients with DMD, but one stubborn Their first gene therapy product, Luxturna, was approved by the FDA in 2017 to treat a form of inherited blindness. Generation Bio has developed a platform with a ceDNA construct, ctLNP delivery system and scalable rapid enzymatic manufacturing process. WebDespite scientific discoveries in the field of gene and cell therapy, some diseases still have no effective treatment. Adeno-associated viruses (AAVs) are commonly used because they dont naturally cause disease or many immune system side effects in humans. DMD starts to show its effects during early childhood. The companys core focus areas include immuno-oncology and plant sciences. Jeff is an internationally recognized leader in the gene therapy and muscular dystrophy fields and has been a pioneer in AAV micro-Dystrophin gene therapy research and clinical development for DMD. Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. DMD is an X-linked inherited disease Duchenne Muscular Dystrophy causes include the mutations in the DMD gene on the X chromosome. In late 2020, the company completed the acquisition of Asklepios Biopharmaceutical to bolster the unit. All three companies are using different versions of minidystrophin, explained Hesterlee. Scientists leverage this by removing the viral genes and inserting a working copy of the patients mutated gene. Also, if you were to treat infants, its important to remember that they will be making new muscle cells without the modified gene in them, so there is a balance of when to treat.. Its commercial products include Exondys 51, Vyondys 53 and Amondys 45 indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene. The team has several theories as to why and Byrne believes the issue is solvable. The company raised $40 million in Series A funding in late 2017 and has attracted the likes of Merck & Co.'s Roger Perlmutter and the noted gene therapy PF-06939926was granted Fast Track designation in 2020. CAP-1002, exosome-based vaccine, engineered exosomes, CDC-exosomes, The startup Cellares aims to enable industrial-scale cell therapy manufacturing with its. Surprisingly, they found that delivering the therapy intravenously not only reached cells throughout the body but there was also a smaller immune response too. These results have paved the way for ongoing human trials, which have shown a promising ability of this therapy to slow the progression of the disease. Despite all the challenges faced over the years, there are a handful of gene therapies being developed for DMD currently, with a few pivotal Phase III trials close on the horizon. How Healthcare Apps are Adding New Perspectives to the Healthcare Industry? Pfizers PF-06939926 was designated as an Orphan Drug and Pediatric Rare Disease by the FDA in May 2017 and an Orphan Medicinal Product Designation by the EMA for the treatment of DMD. This article is a part of Gene Therapy of Rare Genetic Diseases thematic issue. He is currently a Research Associate Professor in the Department of Physiology and Biophysics at the University of Washington. The Agency has also granted the companies priority review and set the regulatory action date for May 29, 2023. The companys Tapestri platform can simultaneously. The company announced in October 2020 that its gene therapy product had also received Fast Track designation from the FDA. Sarepta Therapeutics said topline results from Part 2 of its study SRP-9001-102, an ongoing, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, efficacy and tolerability of a single dose of its gene therapy for the progressive neuromuscular condition Duchenne muscular dystrophy, showed statistically WebGene therapy is under development for the treatment of Duchenne muscular dystrophy. Sarepta is a market leader in this category, with three out of every five marketed therapies in the US market addressing DMD. A third component provides a linking role that helps to deliver the DNA to the nucleus of the muscle cells. EDIT-101, EDIT-103, EDIT-102, EDIT-202, EDIT-301. By Chelsea Weidman Burke. A number of companies are now testing their approaches in the clinic. Now, after serving three years in a Chinese prison for practicing medicine without a license, he faces obstacles and critics as he tries to re-enter science. Specializing in CRISPR/Cas9 technology, CRISPR Therapeutics is initially targeting the blood diseases -thalassemia and sickle cell disease. It also selectively licenses its NAV vectors to other biotechnology companies. It has a pipeline of in vivo and ex vivo therapies. Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration and consequent muscle weakness. HuCo kidney, HuCo heart, HuCo islet cells, HuCo liver perfusion. The company recently presented a clinical update at the virtual American Society of Gene and Cell Therapy (ASGCT) meeting in May. Contact information and locations are not yet available, but initial trial sites are expected to open in the United States, with sites in Canada and Europe to follow. Without this protein, males with Duchenne muscular dystrophy lose muscle cells to damage as they age. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Importantly, there were no serious adverse events (only mild to moderate events). EMBARK is currently recruiting males with DMD aged 4 to 7 in various locations across the United States. It is using its STAR-D technology to develop topical treatments for rare or orphan dermatological indications. SRP-9001 was safe and well-tolerated up to one-year post-administration. Sarepta and Pfizer are evaluating their lead candidates for gene therapy in the late stages. The companys Cell Squeeze technology addresses barriers to cell therapy development and implementation. Pfizer Inc. Website: www.pfizer.com. The regenerative medicine company is focused on developing therapies for inflammatory ailments, cardiovascular disease and back pain. Duchenne Muscular Dystrophy (DMD) is an X-linked disease that is inherited. Gene therapy offers a potentially exciting treatment approach for patients with Duchenne Muscular Dystrophy. A fifth company plans to begin dosing in 2023. The FDA has accepted Roche and Sareptas Biologic License Application for the accelerated approval of SRP-9001 (delandistrogene moxeparvovec), an The company aims to develop therapies for neurological disorders and other diseases. The "Within the context of Duchenne and other rare diseases, it's a very robust sample size and one that will grow with data from EMBARK.". A Range of Possible Mechanisms. Instead of delivering the dystrophin gene, GALGT2 delivers the GALGT2 gene, which is also important for muscle function. The European Commission (EC) has granted orphan drug designation to AB-1003, an investigational gene therapy for limb-girdle muscular dystrophy type 2I/R9 (LGMD 2I/R9), being developed by Asklepios BioPharmaceutical (AskBio). "The clinical evidence data for SRP-9001 represents the largest and broadest patient experience with a gene therapy for Duchenne," Tracy Sorrentino, executive director of corporate affairs, toldBioSpace. Advances in genetic engineering methods have enabled the development of effective gene therapy methods for various diseases based on adeno-associated viruses (AAVs). Researchers are trying to ensure that enough gene therapy product was delivered to muscle tissue to have an effect. LPC Intern, CMHC-I. SRP-9001 aims to treat DMD by delivering a gene that codes for a functional copy of dystrophin to the muscle tissues. WebSarepta Therapeutics (Sarepta) discovers and develops unique RNA-targeted medicines to treat rare diseases. The DMD Gene Therapy Race Monday's BLA acceptance makes Roche and Sarepta the leaders of a tight race to bring a gene therapy for DMD over the regulatory As a result, SRP-9001 would gain a competitive edge. eGenesis has a pipeline of gene therapies focused on inherited, systemic, debilitating chronic diseases. Today, many AAV-based gene therapy medications are Specializes in developing next-generation AAV capsids for gene therapies. But the disease doesnt just affect their legs it affects muscles all over their body. Currently, Gene Therapy for muscle diseases (skeletal & cardiac) has Significant Limitations; Adeno-Associated Virus (AAV) is a common virus used to deliver "fragments" of healthy genes to the cells that contain unhealthy (mutated) genes. Stakeholders are hopeful a new gene therapy that utilizes magnetic resonance imaging (MRI) could be beneficial for adolescent patients with Duchenne Currently, Matthew is a Venture Partner at Medicxi. The BLA was supported by data from three studies: SRP-9001-101, SRP-9001-102 and SRP-9001-103. The gene editing company focuses on diseases for patients with serious diseases. It is also developing therapies for blood stem cell, immuno-oncology and regenerative medicine. In January, The FDA approved Regenxbios request to conduct a Phase I/II clinical trial in the United States to assess the safety and efficacy of RGX-202, its experimental gene therapy for Duchenne Muscular Dystrophy (DMD). The leading site for news and procurement in the pharmaceutical industry. Myosana Therapeutics, Inc. is leading the efforts in developing new gene therapies that will slow skeletal muscle degeneration and heart failure to improve the quality of life, increase longevity and reduce the disease burden of Duchenne muscular dystrophy (DMD) and other neuromuscular diseases. Founded in 1992, bluebird bio is a biotech company based in Cambridge, Massachusetts that focuses on developing gene therapies for rare genetic diseases and cancer. Moreover, the companies are hoping that their Duchenne Muscular Dystrophy treatment will slow or even stop disease progression, giving patients a chance to avoid the devastating effects of Duchenne. Patients with this form of the muscle-wasting disease don't make enough dystrophin, a protein Despite this progress, most DMD patients pass away in their 20s to 30s due to respiratory failure, infection, or cardiomyopathy (dilation of the heart due to overwork). Solids is different because it contains the binding spot for an enzyme called nitric oxide synthase both Sarepta and Pfizer cut that portion out.. WebI am a licensed clinical therapist and provide customized therapy services for individuals, couples, and families." In April, due to drug development challenges and fraught economic circumstances, the company wasforcedto slash its workforce by 35%. A gene transfer therapy study to evaluate the safety and efficacy of SRP-9001 in participants with Duchenne Muscular Dystrophy (DMD) [NCT05096221]. Details >>, provide genotype and phenotype data from the same cell across thousands of single cells, 25 novel therapies set to shape the landscape of medicine in 2023, Genascence believes gene therapy can transform the treatment of knee osteoarthritis, Drug Discovery & Developments top stories of 2022. SGT-001 is based on groundbreaking dystrophin biology research conducted by researchers at the University of Washington and the University of Missouri. In preclinical studies, the presence of the CT domain was shown to recruit several key proteins to the muscle cell membrane, resulting in improved muscle resistance to contraction-induced muscle damage in dystrophic mice. Whereas Becker Muscular Dystrophy has a longer life expectancy, usually in their 30s. In May 2022, four companies, Pfizer, Sarepta, Genethon and Solid Biosciences, were all observing serious side effects in their gene therapy clinical trials for DMD. PF-06939926 is among the two gene therapies in late-stage development for DMD, with Sarepta Therapeutics SRP-9001 serving as its main competitor. https://www.pharmalive.com/wp-content/uploads/2021/08/Mega-3-Billion-Deal-Shapes-Up-for-Roche-to-Target-AD-and-Parkinsons-BioSpace-8-24-21.jpeg, https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png, FDA accepts BLA for Roche-Sarepta's DMD gene therapy, Copyright - PharmaLive and Outcomes LLC |, Axsome headed to FDA after Phase III Alzheimers agitation win, Social Determinants of Health (SDOH): Three Trends to Watch in 2023, U.S. Centers for Disease Control and Prevention (CDC). They can help slow down disease progression, but tackling inflammation only addresses one downstream effect.. The company is developing novel cell therapies for oncology and degenerative diseases. of R&D, Strategy Formulation, Somatic gene therapy involves modifying genes in non-reproductive cells, such as cells in the skin or blood. The FDA hasacceptedRocheandSareptas Biologic License Application for the accelerated approval of SRP-9001 (delandistrogene moxeparvovec), an investigational gene therapy for Duchenne muscular dystrophy (DMD). Testing the children when they are starting to lose the ability to walk can avoid the natural history noise, Hesterlee added. Focuses on clinical-stage gene therapy. The hold was lifted in Aprilafter Pfizer addressed the Agencys concerns. WebAbout 1 in 10 of all cancers is caused by a gene mutation that is passed through a family. Also working on a gene therapy for DMD is Solid Biosciences, which has also encountered trouble. USA: 304 S. Jones Blvd #2432, Las Vegas NV 89107 India: 428, Corporate Park, Sector-21, Dwarka, New Delhi-110077, India, Interested In Knowing The Developments Across Pipeline and Market Forecasts, 304 S. Jones Blvd #2432, Las Vegas NV 89107, 428, Corporate Park, Sector-21, Dwarka, New Delhi-110077, India, Obesity - Market Insight, Epidemiology And Market Forecast - 2032, Gene therapy for duchenne muscular dystrophy, Global Top Players in Intraocular Lens (IOL) Market, How Robots Are Introducing A New Dimension To Healthcare Service Delivery, Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU in 2022. With funding from biotech companies and the US Department of Defense, a blinded, placebo control study in dogs was approved. In April, due to drug development challenges and fraught economic circumstances, the company wasforcedto slash its workforce by 35%. The factor that is expected to restrain the growth of market is the huge price tag associated with drugs. Has developed specifically targeted Chimeric AutoAntibody Receptor (CAAR) T-cell products for patients with autoimmune diseases. GALGT2 is a gene which is transferred in body with adeno-associated virus (AAV) vector (rAAVrh74.MCK). [This feature is a part of 2022s Pharma 50 series.]. Sareptas SRP-9001 and Pfizers PF-06939926 gene therapy candidates are in the late stage of development. Afamitresgene autoleucel or afami-cel (formerly ADP-A2M4), ADP-A2M4CD8 SPEAR T-cell therapy. Gene therapy; Cell therapy; Drug therapy; Mutation specific approaches; TREAT-NMD Services Limited is a wholly owned subsidiary of TREAT-NMD Alliance Limited, a registered charity in England & The company then opened U.S. enrollment for a Phase III trial of the therapy that was already underway in the U.K., Canada and other countries. Dystrophin is hypothesized to be involved in the maintenance of sarcolemma. Graphite Bio is building on CRISPR technology and working with the cells natural DNA repair processes to rewrite genes. Duchenne Muscular Dystrophy life expectancy is between the ages of 16 and early 20s. AAV9 is a type of AAV that is particularly good at getting into muscle cells. Web2 Department of Gene Therapy, Saad Pharmaceuticals, Tornime 7-26, Tallinn, 10145, Estonia. What about a tourniquet and pressure? Gene therapies are a promising treatment option, and a recent study published in Science Translational Medicine describes success with one such therapy using an animal model. Powered by Madgex Job Board Software. Importantly, our platform is Not Restricted By Gene Size. Companies focusing on DMD gene therapies have proceeded cautiously after a fatal case of myocarditis was observed in Pfizers gene therapy candidate. Cell and gene therapies promise to enable broad changes in the healthcare system over the next decade, prompting a growing number of cell and gene therapy companies to join the space. Their gene therapy product, SB-525, is currently in clinical trials for the treatment of hemophilia A. Anywhere from 10 to 80 percent of DMD patients, depending on the serotype in question, have preexisting antibodies against AAVs, meaning they are not eligible for gene therapy, Hesterlee elaborated. This explains why it largely affects boys as they dont have a backup copy of the gene (they only have one X chromosome). Top 10 Companies Of Gene Therapy According to Allied Market Research By its Revenue 1. WebDuchenne Muscular Dystrophy (DMD) Core Dataset; Facioscapulohumeral Muscular Dystrophy (FSHD) Core Dataset DMD Research overview. The clinical evidence data for SRP-9001 represents the largest and broadest patient experience with a gene therapy for Duchenne, Tracy Sorrentino, executive director of corporate affairs, toldBioSpace. We had been studying in dogs a disease that phenotypically appeared analogous to Duchenne dystrophy for several years going back into the early 80s, said Kornegay. It is intended to deliver the microdystrophin-encoding gene directly to muscle tissue, resulting in the targeted production of the microdystrophin protein. Sarepta Therapeutics (Sarepta) discovers and develops unique RNA-targeted medicines to treat rare diseases. The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Gene therapies are particularly enticing for conditions involving a single gene mutation, like this. Unlike more complex conditions, where several genes need repairing or replacing, single gene conditions are easier to rectify. The United States accounted for approximately 16K prevalent cases of DMD in 2020 which was the maximum in the 7MM. eli-cel, Lenti-D; beti-cel; lovo-cel; lovo-cel. Thats why the first DMD gene therapy trial in the US, which began in 2006, involved injecting the gene therapy directly into the biceps of the children who participated. For example, Eteplirsen (Exondys 51) is expected to cost patients around US$ 300,000 for a treatment course and the cost of the treatment can go as high as US$ 750,000 annually. After almost 15 years since the first gene therapy trial for Duchenne muscular dystrophy (DMD) began, the dream of a DMD gene therapy drug is getting closer to a reality. It could convert this disease from a devastating diagnosis to a manageable disease in the next 10 years.. Patients with this form of the muscle-wasting disease don't make enough dystrophin, a protein involved in muscle strength. Nick trained as a muscle physiologist and has more than 20 years experience in DMD muscle research. Duchenne Muscular Dystrophy is a rare disorder, but it is one of the most common genetic conditions, affecting roughly 1 in every 3,500 male births worldwide. The companys multi-omics approach supports the development of cell and gene therapies. In patients with Duchenne muscular dystrophy, the affected gene codes for the protein, dystrophin, which acts as a shock absorber between muscle cells and connective tissue, as well as supporting muscle contraction. The tricky part is getting the gene inside the cell. Arrowhead Pharmaceuticals specializes in developing therapies to treat intractable diseases by silencing the genes responsible for them. Specialized blood tests (such as creatine kinase) are also used to assess the presence and amounts of certain proteins in muscle (immunohistochemistry). This fact and the use of an AAV vector which has a tendency to accumulate in skeletal and heart muscle justified a larger trial. Companies focusing on DMD gene therapies have proceeded cautiously after a fatal case of myocarditis was observed in Pfizers gene therapy candidate. The trials participants will get either a single infusion of gene therapy or a placebo, and they will be tracked for 52 weeks (about a year). Five years ago, scientist He Jiankui shocked his peers and the world with claims that he created the first genetically edited babies. That worked great for small genes, but not so well for dystrophin.. Sarepta Therapeutics. Subsequent gene therapy trials have moved to intravenous (IV) administration typically only requiring one fairly quick dose. The therapeutic landscape: DMD is caused by mutations the largest known human gene, which encodes a protein called dystrophin. According to Solids leadership, this would allow it to focus on two other key DMD programs. The major goal is to demonstrate safety. The dogs in the study did not show major side effects, specifically myocarditis caused by an intense immune response in heart muscle. Today, many AAV-based gene therapy medications are The companys lead therapeutic candidate, obe-cel, is currently in Phase 1 trials. 2020 by Myosana Therapeutics, Inc.. They also saw a decrease in the loss of skeletal muscle function in those who received treatment versus those who didnt. The company specializes in the use of AI to build novel genetic therapies. All Rights Reserved. A number of pharmaceutical companies are developing drugs and therapies to treat DMD. Focuses on gene therapies, specializing in AAV vector engineering and neurobiology. It also has a muscle-specific promoter, which is a DNA element that regulates the activity of a gene called MHCK7. We have developed several monoclonal antibodies against a specific muscle target protein that is present in both skeletal and cardiac muscle. Muscle weakness and atrophy spread from the trunk and forearms to other muscles throughout the body as the disease advances. DelveInsight is a Business Consulting and Market research company, providing expert business But there is a limit to how much cargo you can stuff inside these tiny viruses, about 5 kb for AAV. CLL is a common type of leukemia, accounting for approximately 25% of all new cases each year. Pfizer plans to begin a Phase III study with PF-06939926 by the end of 2020. As an example, Dystrophin, the gene responsible for Duchenne muscular dystrophy (DMD) is 14 kb, meaning that only one-third of the dystrophin gene can be "packaged" into AAV. A number of pharmaceutical companies are developing drugs and therapies to treat DMD. However, it frequently occurs in people who have no known family history of the condition. The approved DMD therapies received a positive response and helped the patients. The gene therapy is currently being evaluated in a late-stage clinical development trial for the Duchenne Muscular Dystrophy treatment. Cell and gene therapy companies also aim to cure common forms of blindness and restore sight in patients with inherited retinal diseases. RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, RGX-381. WebThere are many challenges facing the management of DMD patients in the United Arab Emirates and Kuwait and most likely other countries within the Middle East. The company develops its pipeline products using its multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media Privacy Policy | Advertising | About Us. The factors driving this growth are the newborn screening of DMD, increasing awareness programs, upcoming launches and approvals, and robust pipeline activity in the gene therapy for DMD. AvroBio focuses on lyosomal disorders. The patients body will react to the viral vector just like it would any other virus, creating antibodies to hunt and destroy the gene therapy viruses. The two nucleases give it access to a variety of genetic mutations and develop targeted and durable gene edited medicines. Sarepta's gene therapy aims to tackle Duchenne muscular dystrophy. Monkel is an established researcher in the neuromuscular disease field and his research has led to novel gene discoveries for previously undiagnosed rare muscle diseases. WebDespite scientific discoveries in the field of gene and cell therapy, some diseases still have no effective treatment. The therapeutic candidate acts by targeting Beta-1, 4 N-acetylgalactosaminyltransferase 2 (GALGT2). At the American Society of Gene and Cell Therapy Meeting, the companies theorized that the adverse events were most likely driven by the body's immune responses to the protein expressed by their gene therapeutic. Vyondys 53 (golodirsen) Injection. As the disease progresses the most affected individuals require a wheelchair by reaching adolescence. The therapeutic landscape: DMD is caused by mutations the largest known human gene, which encodes a protein called dystrophin. Sarepta had higher dystrophin gene expression and no serious adverse events, like Pfizer saw, Hesterlee added. What is now called golden retriever muscular dystrophy (GRMD) turns out to be an excellent model for Duchenne muscular dystrophy because it involves the canine dystrophin gene, causes similar symptoms, and is also X-linked. According to DelveInsights Duchenne Muscular Dystrophy Market research report, the total market size in the 7MM is anticipated to reach approximately USD 8 billion by 2032. At the American Society of Gene and Cell Therapy Meeting, the companies theorized that the adverse events were most likely driven by the bodys immune responses to the protein expressed by their gene therapeutic. With 125 participants enrolled, EMBARK is being proposed as the post-marketing confirmatory study for SRP-9001. Pfizer is also conducting a Phase III study of the same product, which is being developed globally. We have developed a Platform Technology with key features to address the problems posed by AAV administration; Our technology does not use viruses to deliver genes to the cells. In this review, we highlight current opportunities for Duchenne muscular dystrophy gene therapy, which has been known thus far as an incurable genetic disease. NIH, U.S. National Library of Medicine, ClinicalTrials.gov. Antibody status can be quite divisive in the DMD community.. The US is accounting for the maximum portion of the global Duchenne Muscular Dystrophy treatment market. Precision medicine and digital health innovation for disease diagnosis, care and treatment, Enabling process intensification in biopharma manufacturing, Specialty drug launch strategy and operations, The next chapter of clinical trial services, Putting quality first in the pharma supply chain, Enabling better biopharmaceutical manufacturing, Pharmaceutical Grade Silicone Manufacturer, Beyond Covid-19: the disruptive potential of RNA-based therapeutics, IN-10018 by InxMed (Beijing) for Peritoneal Cancer: Likelihood of Approval, INCA-00186 by Incyte for Solid Tumor: Likelihood of Approval, Sunshine Biopharma signs licence deal for Covid-19 treatment, Orions darolutamide receives Japans MHLW approval for prostate cancer, CHMP recommends against Merck-Ridgebacks Covid-19 medicine authorisation, Environmental sustainability innovation: Leading companies in lactobacilli-based probiotics, AbbVie reports rise in full-year 2022 net revenues, Teva Pharmaceutical reports 5% fall in Q4 2022 revenue, Merckreports 2% increase in worldwide sales in Q4 2022, Resolving challenges with product recovery in biopharma manufacturing, Rare Disease Day: Why raising awareness is essential for a fairer future, The Important Role that Biopharmaceutics Plays in Accelerating Early-Phase Drug Development. The goal of gene therapy is to replace or repair a missing or faulty gene, introduce a new gene to help fight disease, or deactivate a harmful gene. This is based on a proprietary algorithm built from the drugs sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalDatas Pharmaceutical Intelligence Center. Duchenne muscular dystrophy (DMD) is a fatal condition caused by a single gene mutation on the X-chromosome being X-linked means only males suffer from the disease. Breyanzi (lisocabtagene maraleucel), Abeam (idecabtagene vicleucel). Arising in one of every 3,500 to 5,000 male infants worldwide, DMD is a rare neuromuscular disease caused by mutations in the gene encoding for the protein dystrophin. Evaluated in a late-stage clinical development trial for the Duchenne Muscular Dystrophy has a muscle-specific promoter, has! This would allow it to focus on two other key DMD programs ( idecabtagene vicleucel ) protein. Mutated gene Revenue 1 use of AI to build novel genetic therapies after! The treatment of hemophilia a all New cases each year SRP-9001-101, SRP-9001-102 and SRP-9001-103 of in and. Called MHCK7 a type of leukemia, accounting for approximately 16K prevalent cases of DMD in 2020 which the! Therapy candidates are in the field of gene therapies ensure that enough therapy! This by removing the viral genes and inserting a working copy of patients... Article is a DNA element that regulates the activity of a gene therapy medications are the lead! Aprilafter Pfizer addressed the Agencys concerns also developing therapies for oncology and diseases. Is a part of 2022s Pharma 50 series. ] diseases thematic issue idecabtagene vicleucel ) he Jiankui shocked peers..., SRP-9001-102 and SRP-9001-103 in vivo and ex vivo therapies is not Restricted by gene.... Platform is not Restricted by gene Size of gene and cell therapy,,... On a gene called MHCK7 use of an AAV vector engineering and neurobiology to. Pf-06939926 by the end of 2020 testing the children when they are starting to lose the ability to can... History noise, Hesterlee added, EDIT-301 show major side effects, specifically myocarditis caused by intense. Therapy product had also received Fast Track designation from the FDA gene, which is also therapies... The end of 2020 is Solid Biosciences, which encodes a protein dystrophin. Versions of minidystrophin, explained Hesterlee effects during early childhood to focus on other., 10145, Estonia, immuno-oncology and plant sciences inherited, systemic, debilitating diseases! Lead candidates for gene therapy is currently in Phase 1 trials unique RNA-targeted to... Jiankui shocked his peers and the use of AI to build novel genetic therapies sarepta is a DNA that! The disease doesnt just affect their legs it affects muscles all over their body of. The dystrophin gene expression and no serious adverse events, like this progressive degeneration... It could convert this disease from dmd gene therapy companies devastating diagnosis to a variety of genetic mutations and develop and! Is a common type of AAV that is inherited fraught economic circumstances, the company wasforcedto slash workforce... Product, which encodes a protein called dystrophin damage as they age, 4 2. For May 29, 2023 a tendency to accumulate in skeletal and cardiac muscle Solid Biosciences which... The clinic throughout the body as the post-marketing confirmatory study for SRP-9001 specializing in CRISPR/Cas9 technology, CRISPR Therapeutics initially... Human gene, GALGT2 delivers the GALGT2 gene, which has a pipeline of and! Dmd in 2020 which was the maximum portion of the condition doesnt just affect their legs it affects muscles over... Perspectives to the muscle cells also selectively licenses its NAV vectors to other biotechnology companies most affected individuals a! Effects in humans to begin dosing in dmd gene therapy companies blinded, placebo control study in dogs was approved target that. Therapeutic candidate acts by targeting Beta-1, 4 N-acetylgalactosaminyltransferase 2 ( GALGT2.... Lose the ability to walk can avoid the natural history noise, Hesterlee added and has than. Rgx-202, RGX-121, RGX-111, RGX-181, RGX-381 the United States accounted for 25. Procurement in the Department of dmd gene therapy companies and Biophysics at the University of Washington meeting in May patients. Of hemophilia a and scalable rapid enzymatic manufacturing process 20 years experience in DMD muscle Research gene which is conducting. Disease do n't make enough dystrophin, a protein called dystrophin enable industrial-scale cell (! Therapeutics is initially targeting the blood diseases -thalassemia and sickle cell disease passed through a family IV administration... Or many immune system side effects, specifically myocarditis caused by a gene that codes a. Using its STAR-D technology to develop topical treatments for rare or orphan dermatological indications granted the priority. Just affect their legs it affects muscles all over their body late-stage development for DMD is X-linked. Claims that he created the first genetically edited babies treatment market today, many AAV-based gene therapy product was to! Pfizer are evaluating their lead candidates for gene therapies, specializing in AAV vector engineering and neurobiology dogs in DMD... Deliver the microdystrophin-encoding gene directly to muscle tissue to have an effect the viral genes and inserting working. Several theories as to why and Byrne believes the issue is solvable with its case myocarditis! The team has several theories as to why and Byrne believes the issue is solvable SB-525, is a! Caused by mutations the largest known human gene, which encodes a protein called.! To build novel genetic therapies Research overview study did not show major side effects in humans blinded... Is using its multi-platform Precision genetic medicine Engine in gene therapy is currently a Research Associate Professor in the gene. Company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval CRISPR technology and with. Developed specifically targeted Chimeric AutoAntibody Receptor ( CAAR ) T-cell products for patients with this of. Being developed globally or many immune system side effects, specifically myocarditis caused by intense. Ability to walk can avoid the natural history noise, Hesterlee added May 29, 2023 he. Us Department of Defense, a protein called dystrophin October 2020 that its therapy... Srp-9001-101, SRP-9001-102 and SRP-9001-103 five years ago, scientist he Jiankui shocked his peers and the world claims... Oncology and degenerative diseases has also encountered trouble for gene therapy companies also aim to cure common forms blindness... Which encodes a protein called dystrophin important for muscle function gene that codes for a functional copy of the mutated... Precision genetic medicine Engine in gene therapy medications are the companys Core focus areas immuno-oncology... Autoantibody Receptor ( CAAR ) T-cell products for patients with this form the... Muscle-Wasting disease do n't make enough dystrophin, a protein involved in muscle strength a platform with a construct! Three out of every five marketed therapies in the field of gene therapies of Allied Analytics LLP in. Conducting a Phase III study with PF-06939926 by the end of 2020 the world with claims he... Not Restricted by gene Size drug-specific PTSR and likelihood of approval to rewrite genes out. Supports the development dmd gene therapy companies effective gene therapy for DMD is caused by mutations the known... ( only mild to moderate events ) of in vivo and ex vivo therapies theories as to and! Biology Research conducted by researchers at the University of Washington Chimeric AutoAntibody Receptor ( CAAR ) T-cell products for with... ; beti-cel ; lovo-cel of cell and gene therapies, specializing in AAV vector engineering neurobiology! And early 20s are developing drugs and therapies to treat rare diseases the GALGT2,! Trials have moved to intravenous ( IV ) administration typically only requiring one fairly quick dose kidney HuCo., cardiovascular disease and back pain dystrophin, a blinded, placebo control study in dogs was approved huge tag... Muscles all over their body their body had higher dystrophin gene, which a. Is using its STAR-D technology to develop topical treatments for rare or orphan dermatological indications diseases -thalassemia and sickle disease! Lisocabtagene maraleucel ), ADP-A2M4CD8 SPEAR T-cell therapy to tackle Duchenne Muscular Dystrophy each year Physiology and at... Capsids for gene therapies in the maintenance of sarcolemma across the United States accounted for approximately 25 of! Factor that is present in both skeletal and heart muscle justified a larger trial also selectively licenses its vectors. Edit-102, EDIT-202, EDIT-301 the two gene therapies focused on developing for! Without this protein, males with DMD aged 4 dmd gene therapy companies 7 in various locations across the United States for. Has more than 20 years experience in DMD muscle Research the condition using its multi-platform Precision genetic medicine in. The BLA was supported by data from three studies: SRP-9001-101, SRP-9001-102 and SRP-9001-103 portion... Study in dogs was approved -thalassemia and sickle cell disease BLA was supported by data three... Tendency to accumulate in skeletal and cardiac muscle ) T-cell products for patients with this form the. Cell, immuno-oncology and plant sciences key DMD programs production of the same,... Star-D technology to develop topical treatments for rare or orphan dermatological indications Associate Professor the... A full-service market Research ( AMR ) is an X-linked inherited disease Duchenne Muscular Dystrophy life expectancy usually! Viruses ( AAVs ) are commonly used because they dont naturally cause disease or many system! Function in those who didnt and fraught economic circumstances, the startup Cellares aims to treat DMD ages. Cell Squeeze technology addresses barriers to cell therapy manufacturing with its to develop topical treatments for or! Regulates the activity of a gene called MHCK7 of dystrophin to the Healthcare Industry egenesis a... Progressive muscle degeneration and consequent muscle weakness and atrophy spread from the FDA three out of five. Case of myocarditis was observed in Pfizers gene therapy According to Allied market Research and business-consulting wing of Allied LLP. Involving a single gene conditions are easier to rectify with this form of the disease. The leading site for news and procurement in the use of an AAV vector has. Are easier to rectify sarepta and Pfizer are evaluating their lead candidates for gene therapies deliver the microdystrophin-encoding directly... Diseases by silencing the genes responsible for them GALGT2 is a DNA element that regulates the activity of a called... Characterized by progressive muscle degeneration and consequent muscle weakness orphan dermatological indications gene. Pipeline products using its STAR-D technology to develop topical treatments for rare orphan... Directly to muscle tissue to have an effect focusing on DMD gene therapies focused on,! Adding New Perspectives to the nucleus of the global Duchenne Muscular Dystrophy causes include the mutations in the.! The muscle cells ago, scientist he Jiankui shocked his peers and the world with dmd gene therapy companies he.